Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Companies / H•••• T•••••••••

H•••• T•••••••••

Series CUSh••••••••

H•••• is pioneering the first preventative treatments and functional cures for patients with rare bleeding and thrombotic disorders.

Facts
Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
$157Msum of rounds with a disclosed amount only
Named investors
12
Financing history
1 rounds
  1. Oct 27, 2025
    Series C · $157M (disclosed)
    S•••••••• P••••••• (lead)N••• H••••••• (participant)A••••• B••••••••• (participant)D••• T•••• C•••••• (participant)I•••• (participant)M•• I••••• E••••• (participant)H•••••••• V•• A•••••• A• (participant)A•••• V••••••• (participant)H•••••••• A•••••• A• (participant)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “H•••• T••••••••• Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleeding Disorders”
Investors on record
14 edges
People
0 officers, 0 directors
No officer or director on record.
Timeline
1
  1. Oct 27, 2025
    H•••• T••••••••• announced Series C of $157,000,000, led by S•••••••• P•••••••
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
14 observations
Every observation on this company